Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Glioblastoma: Update Bulletin #1 [May 2018]

Product Code:
596200988
Publication Date:
May 2018
Format:
PDF
Price:
$1,095

This edition presents key opinion leader (KOL) views on recent developments in the Glioblastoma multiforme (GBM) market. Topics covered include: DelMar Pharmaceuticals’ Phase II development for dianhydrogalactitol (VAL-083), in the MGMT-unmethylated GBM patients; PharmAbcine’s announcing that the US FDA had granted Orphan Drug Designation (ODD) to tanibirumab, an anti-VEGFR2 mAb in Phase II trials for treatment of GBM; and Kazia Therapeutics announcing that the US FDA had granted ODD to GDC-0084, an inhibitor of the PI3K/AKT/mTOR pathway, in Phase II trials for GBM.

Business Questions:

• How do KOLs see the development of DelMar’s novel alkylating agent, VAL-083 for GBM?
• What do KOLs expect from VAL-083 Phase II study in the bevacizumab-refractory GBM patients?
• What prospects does VAL-083 have in bevacizumab-naïve MGMT unmethylated patients?
• How do KOLs rate PharmAbcine’s tanibirumab in GBM?
• Will the anti-VEGFR2 mAb shine in bevacizumab-refractory setting? What do KOLs say?
• How do KOLs see tanibirumab plus pembrolizumab (Keytruda) combination in GBM?
• How do KOLs view the PI3K/AKT/mTOR pathway as a target for GBM?
• What safety concerns do experts have with GDC-0084 specifically, and PI3K/AKT/mTOR pathway, generally?
• Are combinations the best way forward with Kazia’s GDC-0084 or can monotherapy reach the market?
• According to KOLs what does GDC-0084 need to achieve to gain approval?

 




customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved